Review
Biochemistry & Molecular Biology
Jennifer K. Matsui, Haley K. Perlow, Alex R. Ritter, Rituraj Upadhyay, Raju R. Raval, Evan M. Thomas, Sasha J. Beyer, Clement Pillainayagam, Justin Goranovich, Shirley Ong, Pierre Giglio, Joshua D. Palmer
Summary: This review discusses the treatment modalities for glioblastoma, the mechanisms of radioresistance, and promising radiosensitizers. Small molecules and immunotherapy agents used in conjunction with radiotherapy have been studied in clinical trials. Recent preclinical studies regarding radiosensitizers for glioblastoma are also discussed.
Review
Oncology
Rui Sun, Albert H. Kim
Summary: With the application of high throughput sequencing technologies at single-cell resolution, researchers have discovered immense cellular and tissue heterogeneity in the tumor microenvironment of glioblastoma. The interactions between malignant and immune cells generate an immunosuppressive microenvironment, while glioma stem cells play a critical role in tumor growth and therapeutic resistance.
CANCER AND METASTASIS REVIEWS
(2022)
Review
Pharmacology & Pharmacy
Cornelia Lee-Thedieck, Peter Schertl, Gerd Klein
Summary: This review provides a comprehensive overview of the extracellular matrix (ECM) in hematopoietic stem cell (HSC) niches and highlights its importance in regulating cellular function and niche structure. The role of different classes of ECM molecules and their interactions with cells are discussed, along with the significance of matrix remodeling and biophysics in HSC niche function. The review also examines the application of current knowledge of ECM in artificial HSC niches for HSC expansion, targeted differentiation, and drug testing.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Clinical Neurology
Lauren Dzikowski, Reza Mirzaei, Susobhan Sarkar, Mehul Kumar, Pinaki Bose, Anita Bellail, Chunhai Hao, V. Wee Yong
Summary: The study investigated the expression of ECM molecules in GBM patients, the effects of different ECM molecules on BTICs in culture, and the association between ECM molecules and MMP-2 and -9 in resected GBM specimens.
Article
Oncology
Tadas K. Rimkus, Austin B. Arrigo, Dongqin Zhu, Richard L. Carpenter, Sherona Sirkisoon, Daniel Doheny, Angelina T. Regua, Grace L. Wong, Sara Manore, Calvin Wagner, Hui-Kuan Lin, Guangxu Jin, Jimmy Ruiz, Michael Chan, Waldemar Debinski, Hui-Wen Lo
Summary: The study found that TUSC2 protein expression is reduced in glioblastoma compared to normal brain due to protein destabilization. NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in glioblastoma. TUSC2 loss promotes glioblastoma progression through upregulation of Bcl-xL and its knockout gene signature predicts poor patient survival.
Review
Immunology
Stoyan Tankov, Paul R. Walker
Summary: Extracellular vesicles play a critical role in mediating communication between glioblastoma cells and immune cells, potentially impacting glioma progression by shaping the tumor microenvironment. These vesicles contain bioactive cargoes that can enhance glioma cell mediated immunosuppressive functions and reprogram tumor infiltrating immune cells, suggesting their importance in cancer-immune crosstalk and as potential diagnostic biomarkers for glioma.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Agathe L. Chedeville, Patricia A. Madureira
Summary: Glioblastoma (GB) is the deadliest type of primary brain tumor with a median survival time of 16 months post-diagnosis, and radiotherapy remains the most effective treatment despite the common resistance observed in GB patients. Understanding the role of low tumor oxygenation (hypoxia) in radioresistance is crucial for developing novel strategies to improve tumor cell sensitivity to radiotherapy.
Article
Multidisciplinary Sciences
Qing Guo, Shuai Shen, Gefei Guan, Chen Zhu, Cunyi Zou, Jingyuan Cao, Wen Cheng, Xiaoyan Xu, Juanhan Yu, Zhiguo Lin, Guoli Wang, Ling Chen, Peng Cheng, Anhua Wu
Summary: Glioblastoma (GBM) shares common signaling pathways involving TIM-3, an immune checkpoint, between tumor and non-tumor cells. The study reveals that TIM-3 in glioma cells not only regulates the malignant behaviors of glioma cells but also induces macrophage migration and transition to an anti-inflammatory/protumorigenic phenotype through the TIM-3/IL6 signal. Blocking this feedback loop may provide a novel therapeutic strategy for GBM.
Article
Oncology
Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Saya Ozaki, Yonehiro Kanemura, Satoshi Suehiro, Yoshihiro Ohtsuka, Shohei Kohno, Shiro Ohue, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Summary: The poor prognosis of glioblastoma multiforme (GBM) is mainly attributed to highly invasive glioma stem-like cells (GSCs) in tumors. Differential regulation by hypoxia levels influences the behavior of GSCs, demonstrating the key role of interaction between CD44 and osteopontin in tumor progression in GBM.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Neurosciences
Sajina Shakya, Anthony D. Gromovsky, James S. Hale, Arnon M. Knudsen, Briana Prager, Lisa C. Wallace, Luiz O. F. Penalva, H. Alex Brown, Bjarne W. Kristensen, Jeremy N. Rich, Justin D. Lathia, J. Mark Brown, Christopher G. Hubert
Summary: Glioblastoma displays significant cellular and metabolic heterogeneity, with striking differences in lipid metabolism across different microenvironments, and cancer stem cells (CSCs) also show altered lipid metabolism. The differences in lipid metabolism may not only be a product of the microenvironment, but also a reflection of cellular state, providing new insights into therapeutic targets for GBM.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2021)
Article
Engineering, Environmental
Xuefeng Zhang, Qing Guo, Zongren Zhao, Peng Cheng, Anhua Wu, Hongmei Liu
Summary: A new therapeutic strategy combining anticancer drugs and immunotherapy was developed to target tumor-associated macrophages and glioma stem cells, leading to inhibited tumor growth and prolonged survival in a mouse model of glioblastoma. These findings highlight the importance of this approach for the treatment of glioblastoma.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Rashmi Srivastava, Meghana Dodda, Han Zou, Xuejun Li, Baoli Hu
Summary: Glioblastoma (GBM) is a common and deadly brain tumor, which remains largely incurable despite intensive multimodal treatment. Targeted therapies, such as antiangiogenesis therapy and immunotherapy, show promise in treating GBM. Single-cell transcriptomics reveals the heterogeneity and dynamics of tumor cells during GBM development.
ANTIOXIDANTS & REDOX SIGNALING
(2023)
Review
Medicine, Research & Experimental
Nathaniel H. Boyd, Anh Nhat Tran, Joshua D. Bernstock, Tina Etminan, Amber B. Jones, G. Yancey Gillespie, Gregory K. Friedman, Anita B. Hjelmeland
Summary: Tumor microenvironments result from cellular alterations in cancer that promote unrestricted growth and angiogenesis, with hypoxia and acidic stress known to modulate therapeutic resistance. Understanding the interplay between tumor microenvironments and glioma stem cells is crucial for developing better treatment options for glioblastoma.
Article
Materials Science, Biomaterials
Yixiao Cui, Paul Lee, Jesse J. Reardon, Anna Wang, Skylar Lynch, Jose J. Otero, Gina Sizemore, Jessica O. Winter
Summary: Researchers used a 3D collagen I-hyaluronic acid hydrogel material to study the interaction between glioblastoma cells and astrocytes. They observed different migration behaviors and found differential gene expression in immune response, inflammation, and cytokine signaling.
JOURNAL OF MATERIALS CHEMISTRY B
(2023)
Review
Immunology
Hassan Dianat-Moghadam, Reza Nedaeinia, Mohsen Keshavarz, Mehdi Azizi, Mohammad Kazemi, Rasoul Salehi
Summary: Angiogenesis is a characteristic of cancer biology, and current therapies targeting tumor vasculature have limitations. By combining immunotherapy and nanocarriers, the efficacy of antiangiogenic agents could be improved while reducing the dosage of chemotherapy drugs. Furthermore, the combination of immunotherapies and nano-based delivery systems can extend the window of vascular normalization and overcome the challenges of antiangiogenic agents in treatment.
FRONTIERS IN IMMUNOLOGY
(2023)